HLX208 (BRAF V600E Inhibitor) in Combination With Trimetinib in Patients With Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
A phase I clinical trial evaluating the safety, tolerability, pharmacokinetics, and initial
efficacy of HLX208 (BRAF V600E inhibitor) in combination with trimetinib in patients with
advanced solid tumors